Search
Close
Search
Advanced Search
Search Menu

Abstract

A previous placebo-controlled trial has shown that biodegradable 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) wafers (Gliadel wafers) prolong survival in patients with recurrent glioblastoma multiforme. A previously completed phase 3 trial, also placebo controlled, in 32 patients with newly diagnosed malignant glioma also demonstrated a survival benefit in those patients treated with BCNU wafers. Because of the small number of patients in that trial, a larger phase 3 trial was performed to confirm these results. Two hundred forty patients were randomized to receive either BCNU or placebo wafers at the time of primary surgical resection; both groups were treated with external beam radiation postoperatively. The two groups were similar for age, sex, Karnofsky performance status (KPS), and tumor histology. Median survival in the intent-to-treat group was 13.9 months for the BCNU wafer-treated group and 11.6 months for the placebo-treated group (log-rank P-value stratified by country = 0.03), with a 29% reduction in the risk of death in the treatment group. When adjusted for factors affecting survival, the treatment effect remained positive with a risk reduction of 28% (P = 0.03). Time to decline in KPS and in 10/11 neuroperformance measures was statistically significantly prolonged in the BCNU wafer-treated group (P ≤ 0.05). Adverse events were comparable for the 2 groups, except for CSF leak (5% in the BCNU wafer-treated group vs. 0.8% in the placebo-treated group) and intracranial hypertension (9.1% in the BCNU wafer-treated group vs. 1.7% in the placebo group). This study confirms that local chemotherapy with BCNU wafers is well tolerated and offers a survival benefit to patients with newly diagnosed malignant glioma.

References

Andrews, D.W., Das, R., Kim, S., Zhang, J., and Curtis, M. (

1997
) Tech netium-MIBI as a glioma imaging agent for the assessment of multi-drug resistance.
Neurosurgery
40
,
1323
-1334.

Bigner, D.D., Brown, M., Coleman, R.E., Friedman, A.H., Friedman, H.S., McLendon, R.E., Bigner, S.H., Zhao, X.G., Wikstrand, C.J., Pegram, C.N., Kerby, T., and Zalutsky, M.R. (

1995
) Phase 1 studies of treatment of malig nant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Mel-14 F(ab')2—A preliminary report.
J. Neurooncol.
24
,
109
-122.

Brada, M., and Yung, W.K.A. (

2000
) Clinical trial end points in malignant glioma: Need for effective trial design strategy.
Semin. Oncol.
27
(Suppl. 6),
11
-19.

Brem, H., Tamargo, R.J., Olivi, A., Pinn, M., Weingart, J.D., Wharam, M., and Epstein, J.I. (

1994
) Biodegradable polymers for controlled delivery of chemotherapy with and without radiation therapy in the monkey brain.
J. Neurosurg.
80
,
283
-290.

Brem, H., Piantadosi, S., Burger, P.C., Walker, M., Selker, R., Vick, N.A., Black, K., Sisti, M., Brem, S., Mohr, G., Morawetz, R., and Schold, S.C. (

1995
) Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas.
Lancet
345
,
1008
-1012.

Cairncross, J.G., Macdonald, D.R., and Ramsay, D.A. (

1992
) Aggressive oligodendroglioma: A chemosensitive tumor.
Neurosurgery
31
,
78
-82.

Chang, S.M., and Prados, M.D. (

1995
) Chemotherapy for gliomas.
Curr. Opinion Oncol.
7
,
207
-213.

Cristante, L., Siepmann, G., Westphal, M., Hagel, C., and Hermann, H.D. (

1992
) Superselective application of cis-platinum in recurrent human glioblastoma.
Reg. Cancer Treat.
4
,
188
-194.

Culver, K.W., Ram, Z., Wallbridge, S., Ishii, H., Oldfield, E.H., and Blaese, R.M. (

1992
) In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors.
Science
256
,
1550
-1552.

Fine, H.A., Dear, K.B.G., Loeffler, J.S., Black, P.M., and Canellos, G.P. (

1993
) Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant glioma in adults.
Cancer
71
,
2585
-2597.

Fontana, A., Constam, D.B., Frei, K., Malipiero, U., and Pfister, H.W. (

1992
) Modulation of the immune response by transforming growth factor β.
Int. Arch. Allerg. Immunol.
99
,
1
-7.

Giese, A., and Westphal, M. (

1996
) Glioma invasion in the central nervous system.
Neurosurgery
39
,
235
-252.

Hildebrand, J., DeWitte, O., Dietrich, P.Y., and de Tribolet, N. (

1997
) Man agement of malignant brain tumors.
Eur. Neurol.
38
,
238
-253.

Hochberg, F., and Pruitt, A. (

1980
) Assumptions in the radiotherapy of glioblastoma.
Neurology
30
,
907
-911.

Jachimczak, P., Bogdahn, U., Schneider, J., Behl, C., Meixensberger, J., Apfel, R., Dorries, R., Schlingensiepen, K.H., and Brysch, W. (

1993
) The effect of transforming growth factor-β 2–specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in malig nant glioma.
J. Neurosurg.
78
,
944
-951.

Kleihues, P., and Cavenee, W.K. (

2000
) Pathology and Genetics of Tumours of the Nervous System.
World Health Organization Classification of Tumours
. Lyon: IARC Press.

Köppen, J.A., Herrmann, H.D., Giese, A., Franz, H.R., Raschdorff, C., von Koschitzky, H., and Westphal, M. (

1991
) Lymphokine-activated killer cells, interleukin-2 and tumor necrosis factor a in malignant glioma: Clin ical and laboratory findings.
Reg. Cancer Treat.
3
,
338
-344.

Kramm, C.M., Sena-Esteves, M., Barnett, F.H., Rainov, N.G., Schuback, D.E., Yu, J.S., Pechan, P.A., Paulus, W., Chiocca, E.A., and Breakefield, X.O. (

1995
) Gene therapy for brain tumors.
Brain Pathol.
5
,
345
-381.

Laske, D.W., Youle, R.J., and Oldfield, E.H. (

1997
) Tumor regression with regional distribution of the targeted toxin TF-CRM 107 in patients with malignant brain tumors.
Nat. Med.
3
,
1362
-1368.

Lesser, G.J., and Grossman, S. (

1994
) The chemotherapy of high-grade astrocytomas.
Semin. Oncol.
21
,
220
-235.

Levin, V.A., Leibel, S.A., and Gutin, P.H. (

1997
) Neoplasms of the central nervous system. In: De Vita, V.T., Jr., Hellman, S., and Rosenberg, S.A. (Eds.),
Cancer: Principles & Practice of Oncology, 5th ed.
, Vol.
2
. Philadelphia: Lippincott-Raven Publishers, pp.
2022
-2082.

Lieberman, D.M., Laske, D.W., Morrison, P.F., Bankiewicz, K.S., and Oldfield, E.H. (

1995
) Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion.
J. Neurosurg.
82
,
1021
-1029.

Martuza, R.L. (

1997
) Act locally, think globally.
Nat. Med.
3
,
1323
.

Merchant, R.E., Ellison, M.D., and Young, H.F. (

1990
) Immunotherapy for malignant glioma using human recombinant interleukin-2 and activated autologous lymphocytes. A review of pre-clinical and clinical investigations.
J. Neurooncol.
8
,
173
-188.

Merchant, R.E., Baldwin, N.G., Rice, C.D., and Bear, H.D. (

1997
) Adoptive immunotherapy of malignant glioma using tumor-sensitized T lympho cytes.
Neurol. Res.
19
,
145
-152.

Mesnil, M., Piccoli, C., Tiraby, G., Willecke, K., and Yamasaki, H. (

1996
) Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins.
Proc. Natl. Acad. Sci. USA
93
,
1831
-1835.

Prados, M.D., and Levin, V. (

2000
) Biology and treatment of malignant glioma.
Semin. Oncol.
27
(Suppl. 6),
1
-10.

Rainov, N.G., on behalf of the FL1328 International Study Group (

2000
) A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme.
Hum. Gene Ther.
11
,
2389
-2401.

Ram, Z., Culver, K.W., Oshiro, E.M., Viola, J.J., DeVroom, H.L., Otto, E., Long, Z., Chiang, Y., McGarrity, G.J., Muul, L.M, Katz, D., Blaese, R.M., and Oldfield, E.H. (

1997
) Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells.
Nat. Med.
3
,
1354
-1361.

Reist, C.J., Archer, G.E., Kurpad, S.N., Wikstrand, C.J., Vaidyanathan, G., Willingham, M.C., Moscatello, D.K., Wong, A.J., Bigner, D.D., and Zalutsky, M.R. (

1995
) Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: Use of the tyramine cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts.
Cancer Res.
55
,
4375
-4382.

Reulen, H.J., Graber, S., Huber, P., and Ito, U. (

1988
) Factors affecting the extension of peritumoural brain oedema. A CT-study.
Acta Neurochir. (Wien.)
95
,
19
-24.

Riva, P., Franceschi, G., Arista, A., Frattarelli, M., Riva, N., Cremonini, A.M., Guiliani, G., and Casi, M. (

1997
) Local application of radiolabeled mon oclonal antibodies in the treatment of high grade malignant gliomas: A six year clinical experience.
Cancer
80
,
2733
-2742.

Salcman, M. (

1994
) The value of cytoreductive surgery.
Clin. Neurosurg.
41
,
464
-488.

Shapiro, W.R., Green, S.B., Burger, P.C., Selker, R.G., VanGilder, J.C., Robert son, J.T., Mealey, J., Jr., Ransohff, J., and Mahaley, M.S., Jr. (

1992
) A ran domized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5–fluorouracil, for newly diagnosed patients with malignant glioma.
J. Neurosurg.
76
,
772
-781.

Stewart, L.A. (

2002
) Chemotherapy in adult high-grade glioma: A systematic review and meta-analysis of individual patient data from 12 ran domised trials.
Lancet
359
,
1011
-1018.

Valtonen, S., Timonen, U., Toivanen, P., Kalimo, H., Kivipelto, L., Heiskanen, O., Unsgaard, G., and Kuurne, T. (

1997
) Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: A randomized double-blind study.
Neurosurgery
41
,
44
-49.

Walker, M.D., Green, S.B., Byar, D.P., Alexander, E., Jr., Batzdorf, U., Brooks, W.H., Hunt, W.E., MacCarty, C.S., Mahaley, M.S., Mealey, J., Jr., Owens, G., Ransohoff, J., 2nd, Robertson, J.T. Shapiro, W.R., Smith, K.R., Jr., Wilson, C.B., and Strike, T.A. (

1980
) Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery.
N. Engl. J. Med.
303
,
1323
-1329.

Wersall, P., Ohlsson, I., Biberfeld, P., Collins, V.P., von Krusenstjerna, S., Larsson, S., Mellstedt, H., and Boethius, J. (

1997
) Intratumoral infusion of the monoclonal antibody, mAb 425, against the epidermal-growth-factor receptor in patients with advanced malignant glioma.
Cancer Immunol. Immunother.
44
,
157
-164.

Westphal, M., and Giese, A. (

1999
) Local control of gliomas: The next best step—a good step?
Front. Radiat. Ther. Oncol.
33
,
214
-226.

Author notes

Department of Neurosurgery, University Hospital Eppendorf, Hamburg, Germany (M.W.);Guilford Pharmaceuticals, Baltimore, MD 21224, USA (D.C.H., E.B.);Aventis Pharma France, Paris, France (P.D., R.O.);Walton Centre for Neurology and Neurosurgery, Liverpool, UK (P.C.W.);Department of Neurosurgery, Western General Hospital, Edinburgh, Scotland (I.R.W.);Department of Neurosurgery, Topeliuksenkatu 5, Helsinki, Finland (J.J.);Department of Neurosurgery, Chaim Sheba Medical Center, Tel-Aviv, Israel (Z.R.)

© 2003 by the Society for Neuro-Oncology
Topic:
Issue Section:
Clinical Therapy Trials—Drugs
Download all slides